News & Research

Hyperbaric Oxygen Therapy has been used for the better part of two centuries. Search our  arhives below for past HBOT news and research or scroll down for the latest.

The Latest HBOT News & Research

Clinical Trial – Delayed Recompression for Decompression Sickness

Decompression sickness syndrome (DCS) is caused by microbubbles forming in blood vessels or
tissues during a reduction in environmental pressure (decompression). Bubbles have
mechanical, embolic and biochemical effects with manifestations ranging from none to fatal.
By reducing bubble volume and hastening inert gas elimination, recompression therapy with
hyperbaric treatment remains the main therapy for DCS. The most common hyperbaric protocol
used, is based on US Navy Treatment table 6, started as early as possible after surfacing.
The outcome of hyperbaric therapy varies with reported complete resolution in 13%-63% of the
patients suffering from severe DCS, and in 73%-100% of the patients with mild-moderate DCS.

The significance of time to recompression is controversial. It has been suggested that early
hyperbaric treatment improves the outcome by decreasing bubble size and avoiding further
tissue injury. However, in recent studies time to recompression had very little effect on
clinical recovery. Moreover, the time beyond which hyperbaric treatment isn’t effective has
not been determined yet.

The aim of this study was to evaluate the clinical outcome of delayed hyperbaric treatment to
divers who referred to tertiary care hospital hyperbaric unit, more than 48 hours after
surfacing. The clinical outcome of the delayed hyperbaric treatments was compared to early
treatments given at the same hyperbaric unit.

Clinical Trial – The Effect of Hyperbaric Chamber Treatment on Patients With Diabetic Retinopathy

Diabetic retinopathy (DR) is a common complication of diabetes and is divided into non
proliferative DR and proliferative DR. The damage is caused by either macular edema, macular
ischemia that can be followed by vascular proliferation.

Hyperbaric chamber treatment assists in increasing the amount of oxygen in the plasma and in
the tissues and has been proven to be beneficial in treating different wounds in diabetic
patients but its effect hasn’t been tested in diabetic retinopathy yet.

This study will recruit 40 diabetic patients who are scheduled for hyperbaric treatment due
to different indications such as chronic wounds or radiation damages and who also have
diabetic retinopathy. These patients will undergo opthalmic physical examination including
fundus photography and OCT (Optical Coherence Tomography – optical IR retinal photography).
Screening for these patients will be conducted at the Hyperbaric chamber at Assaf Harofe
Medical Center for all diabetic patients prior to their first treatment.